title: Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats.
abstract: BACKGROUND
  Since an originally anti-ulcer stable gastric pentadecapeptide BPC 157 (PL 14736) was shown to promote healing of injured striated muscle and smooth muscle in the gastrointestinal tract, we explored its therapeutic potentials for leak point pressure (LPP) recovery in rat stress urinary incontinence (SUI) after transabdominal urethrolysis (TU) and prolonged vaginal dilatation (VD).
  
  
  METHODS
  During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day). Vesicourethral segments were harvested for immunohistochemical evaluation.
  
  
  RESULTS
  All BPC 157 regimens counteracted decrease of LPP values in TU-rats and VD-rats. Additionally, BPC 157-TU rats (µg-intraperitoneally or per-orally) and BPC 157-VD rats (µg intraperitoneally) reached LPP values originally noted in healthy rats. Conversely, in healthy rats, BPC 157 did not alter LPP. Immunohistochemical studies revealed higher desmin (delineates striated organization of skeletal muscle), smooth muscle actin, and CD34 (angiogenic marker) positivity within the urethral wall in BPC 157-treated rats vs. controls, as well as overall preserved muscle/connective tissue ratio assessed with Mallory's trichrome staining.
  
  
  CONCLUSIONS
  Pentadecapeptide BPC 157, applied parenterally or per-orally, appears to ameliorate the SUI in rat models, improving the otherwise detrimental course of healing after VD and TU, which may be analogous to human injury. These beneficial effects may possibly be selectively used in future strategies for treatment of SUI.
authors.affiliation: General Hospital "Dr. Josip Bencevic", Slavonski Brod, Croatia.
authors.forename: Ivan
authors.initials: I
authors.lastname: Jandric
authors.forename: Hrvoje
authors.initials: H
authors.lastname: Vrcic
authors.forename: Marica
authors.initials: M
authors.lastname: Jandric Balen
authors.forename: Danijela
authors.initials: D
authors.lastname: Kolenc
authors.forename: Luka
authors.initials: L
authors.lastname: Brcic
authors.forename: Bozo
authors.initials: B
authors.lastname: Radic
authors.forename: Domagoj
authors.initials: D
authors.lastname: Drmic
authors.forename: Sven
authors.initials: S
authors.lastname: Seiwerth
authors.forename: Predrag
authors.initials: P
authors.lastname: Sikiric
mesh_terms: D000199:Actins / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D007263:Infusions, Parenteral; D009130:Muscle, Smooth / Q000473:pathology; D010446:Peptide Fragments / Q000627:therapeutic use*; D011506:Proteins / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D014521:Urethra / Q000187:drug effects* / Q000473:pathology; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*; D014621:Vagina / Q000473:pathology; D014945:Wound Healing
chemical_list: D000199:Actins; D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; C083833:BPC 157